View the article online at http://citywire.co.uk/wealth-manager/article/a747176
Glaxo sells cancer arm to Novartis in £10bn deal
by Dylan Lobo on Apr 22, 2014 at 08:11
Swiss drugmaker Novartis has acquired GlaxoSmithKline's cancer-drug business.
In a deal which could be worth as much as $16 billion (£9.5 billion), Novartis separately said it would form a consumer-health care venture with Glaxo and sell it's animal business to Eli Lilly for $5.4 billion.
The new consumer business is expected to generate revenues of around £6.5 billion with Glaxo owning a majority 63.5% stake.
'Opportunities to build greater scale and combine high quality assets in vaccines and consumer health care are scarce,” Glaxo CEO Andrew Witty said in a statement. “With this transaction, we will substantially strengthen two of our core businesses and create significant new options to increase value for shareholders.'
News sponsored by:
As the UK coalition government strives to rebalance the national economy, so called 'reshoring' looks set to play an increasingly important role in economic recovery.
Today's top headlines
With talk on interest rates on the horizon, our latest roundtable debate covers income investing against a changing backdrop
On the road
on Jul 24, 2014 at 10:59